tetano
Editor, Senior Moderator
Eur J Med Chem. 2018 Feb 1;146:220-231. doi: 10.1016/j.ejmech.2018.01.050. [Epub ahead of print]
[h=1]Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.[/h] Ju H[SUP]1[/SUP], Zhang J[SUP]1[/SUP], Sun Z[SUP]1[/SUP], Huang Z[SUP]1[/SUP], Qi W[SUP]2[/SUP], Huang B[SUP]3[/SUP], Zhan P[SUP]1[/SUP], Liu X[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Inspired by our initial discovery about a series of neuraminidase (NA) inhibitors targeting the 150-cavity, in present study, we designed, synthesized, and biologically tested a panel of novel oseltamivir derivatives with C-1 modification, targeting the 430-cavity, an additional binding site which widely and stably existed in both group-1 and group-2 NAs. Some of the synthesized compounds displayed robust anti-influenza potencies against H5N1 and H5N6 viruses. Among them, compound 8b exerted the greatest inhibition, with IC[SUB]50[/SUB] values of 0.088 and 0.097 μM and EC[SUB]50[/SUB] values of 4.26 and 1.31 μM against H5N1 and H5N6 strains, respectively, which are similar to those of oseltamivir carboxylate (OSC). And its potency against mutant H5N1-H274Y NA was just 7-fold weaker than OSC. Molecular modeling revealed the elongated group at C-1 position being projected toward the 430-cavity. Notably, although compound 8b was not sensitive toward H5N1 strain relative to OSC in the embryonated egg model, it displayed greater anti-influenza virus effect against H5N6 strain than OSC at the concentration of 10 mmol/L. Overall, this work provided unique insights in the discovery of potent inhibitors against both group-1 and group-2 NAs.
[h=4]KEYWORDS:[/h] 430-Cavity; Embryonated egg model; Influenza virus; Neuraminidase inhibitors; Oseltamivir derivatives
PMID: 29407952 DOI: 10.1016/j.ejmech.2018.01.050
[h=1]Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.[/h] Ju H[SUP]1[/SUP], Zhang J[SUP]1[/SUP], Sun Z[SUP]1[/SUP], Huang Z[SUP]1[/SUP], Qi W[SUP]2[/SUP], Huang B[SUP]3[/SUP], Zhan P[SUP]1[/SUP], Liu X[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Inspired by our initial discovery about a series of neuraminidase (NA) inhibitors targeting the 150-cavity, in present study, we designed, synthesized, and biologically tested a panel of novel oseltamivir derivatives with C-1 modification, targeting the 430-cavity, an additional binding site which widely and stably existed in both group-1 and group-2 NAs. Some of the synthesized compounds displayed robust anti-influenza potencies against H5N1 and H5N6 viruses. Among them, compound 8b exerted the greatest inhibition, with IC[SUB]50[/SUB] values of 0.088 and 0.097 μM and EC[SUB]50[/SUB] values of 4.26 and 1.31 μM against H5N1 and H5N6 strains, respectively, which are similar to those of oseltamivir carboxylate (OSC). And its potency against mutant H5N1-H274Y NA was just 7-fold weaker than OSC. Molecular modeling revealed the elongated group at C-1 position being projected toward the 430-cavity. Notably, although compound 8b was not sensitive toward H5N1 strain relative to OSC in the embryonated egg model, it displayed greater anti-influenza virus effect against H5N6 strain than OSC at the concentration of 10 mmol/L. Overall, this work provided unique insights in the discovery of potent inhibitors against both group-1 and group-2 NAs.
[h=4]KEYWORDS:[/h] 430-Cavity; Embryonated egg model; Influenza virus; Neuraminidase inhibitors; Oseltamivir derivatives
PMID: 29407952 DOI: 10.1016/j.ejmech.2018.01.050